Duncker Streett & Co’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-6,465
Closed -$642K 563
2019
Q3
$642K Sell
6,465
-1,900
-23% -$181K 0.15% 151
2019
Q2
$773K Sell
8,365
-400
-5% -$38K 0.17% 137
2019
Q1
$827K Buy
8,765
+1,070
+14% +$93.6K 0.19% 128
2018
Q4
$493K Sell
7,695
-1,040
-12% -$76.8K 0.13% 164
2018
Q3
$782K Buy
8,735
+230
+3% +$20.3K 0.18% 141
2018
Q2
$675K Sell
8,505
-4,200
-33% -$349K 0.17% 148
2018
Q1
$1.13M Buy
12,705
+520
+4% +$49.9K 0.29% 110
2017
Q4
$1.27M Buy
12,185
+1,640
+16% +$185K 0.33% 97
2017
Q3
$1.54M Buy
10,545
+2,990
+40% +$407K 0.47% 68
2017
Q2
$981K Buy
7,555
+640
+9% +$78.4K 0.31% 98
2017
Q1
$860K Buy
6,915
+420
+6% +$50.3K 0.27% 107
2016
Q4
$752K Buy
6,495
+340
+6% +$37.9K 0.25% 113
2016
Q3
$643K Sell
6,155
-100
-2% -$10.8K 0.22% 125
2016
Q2
$617K Hold
6,255
0.22% 117
2016
Q1
$626K Sell
6,255
-400
-6% -$41.2K 0.23% 117
2015
Q4
$797K Sell
6,655
-400
-6% -$46.3K 0.3% 96
2015
Q3
$763K Sell
7,055
-520
-7% -$64.5K 0.3% 95
2015
Q2
$877K Sell
7,575
-2,000
-21% -$229K 0.31% 96
2015
Q1
$1.1M Buy
9,575
+200
+2% +$23.9K 0.36% 82
2014
Q4
$1.05M Buy
9,375
+300
+3% +$31.6K 0.34% 87
2014
Q3
$860K Buy
9,075
+850
+10% +$76.7K 0.29% 108
2014
Q2
$706K Buy
8,225
+4,175
+103% +$317K 0.23% 128
2014
Q1
$283K Buy
4,050
+250
+7% +$19.8K 0.1% 211
2013
Q4
$321K Hold
3,800
0.12% 192
2013
Q3
$293K Sell
3,800
-4,000
-51% -$280K 0.12% 189
2013
Q2
$456K Buy
+7,800
New +$469K 0.17% 150

Other funds holding CELG

Duncker Streett & Co's CELG Position: Q4 2019 in Review

Duncker Streett & Co sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 6,465 shares — an estimated $642K sold.

Duncker Streett & Co first reported a position in CELG in Q2 2013 and held it in 26 quarters. The position peaked at $1.54M in Q3 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Duncker Streett & Co reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Duncker Streett & Co sold 6,465 Celgene Corp shares in Q4 2019, an estimated $642K.
  • Duncker Streett & Co first reported a position in Celgene Corp in Q2 2013 and held it in 26 quarters.
  • Duncker Streett & Co's Celgene Corp position peaked at $1.54M in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Duncker Streett & Co's 13F filing for Q4 2019, filed 27 Jan 2020.